Remeron More Effective, Faster Working Than Cipramil or Paxil, Study Shows
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Remeron More Effective, Faster Working Than Cipramil or Paxil, Study Shows

PARIS, FRANCE -- Nov. 3, 1998 -- Study results presented today show that Organon’s Remeron® (mirtazapine) is more effective and has a faster onset of action than the selective serotonin reuptake inhibitors Cipramil® (citalopram) and Paxil® (paroxetine).

"These studies are very persuasive and add to growing evidence that dual-acting antidepressants like Remeron, which increase levels of both noradrenaline and serotonin, are genuinely more effective than the selective serotonin reuptake inhibitors," said professor Siegfried Kasper, professor of psychiatry at the University of Vienna, who presented the findings at the European College of Neuropsychopharmacology meeting. "In addition, the results from these studies suggest Remeron’s action is not just stronger, but also quicker."

These results follow the recent publication in the Journal of Clinical Psychiatry which shows that Remeron shows superior efficacy to Prozac®(fluoxetine).

In the eight-week, head-to-head, double-blind trial of Remeron and Cipramil involving over 260 patients, those taking Remeron showed a significantly greater improvement in symptoms of depression at week two compared to Cipramil. The dose ranges were 15 to 60 mg for Remeron and 20 to 60 mg for Cipramil, in line with usual clinical practice.

In the trial against Paxil, based on a similar design, patients taking Remeron had a statistically-significant greater improvement in symptoms of depression at week one than those taking paroxetine. Moreover, the number of patients responding to Remeron was greater at all timepoints, reaching statistical significance at both week one and week four.

In both comparative studies, patients taking Remeron experienced less SSRI-associated side effects such as headache, nausea and sweating and there was no statistical difference in the number of patients experiencing somnolence.

Related Links: Remeron, Paxil and Organon

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities